GUPEA >
Sahlgrenska Academy / Sahlgrenska akademin >
Institute of Clinical Sciences / Institutionen för kliniska vetenskaper >
Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper >

Clinical implementation of novel diagnostic biomarkers for epithelial ovarian cancer - Can we improve diagnosis?


Please use this identifier to cite or link to this item: http://hdl.handle.net/2077/63236

Files in This Item:

File Description SizeFormat
gupea_2077_63236_2.pdfThesis frame6275KbAdobe PDF
View/Open
gupea_2077_63236_4.pdfAbstract292KbAdobe PDF
View/Open
Title: Clinical implementation of novel diagnostic biomarkers for epithelial ovarian cancer - Can we improve diagnosis?
Authors: Lycke, Maria
E-mail: maria.lycke@gu.se
Issue Date: 1-Apr-2020
University: University of Gothenburg. Sahlgrenska Academy
Institution: Institute of Clinical Sciences. Department of Obstetrics and Gynecology
Parts of work: I. Lycke M, Kristjansdottir B, Sundfeldt K A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index Gynecologic oncology 2018;151:159-165
VIEW ARTICLE


II. Lycke M, Ulfvenborg B, Kristjansdottir B, Sundfeldt K Increased diagnostic accuracy of adnexal tumors with a combination of established algorithms and biomarkers. J. Clin. Med. 2020, 9, 299
VIEW ARTICLE


III. Lycke M, Ulfvenborg B, Lauesgaard J, Kristjansdottir B, Sundfeldt K 2020 Consideration should be given smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics. Manuscript

IV. Wang Y, Lu L, Douville C, Cohen J.D, Yen T, Kinde I, Sundfeldt K, Kjaer S.K, Hruban R.H, Shih I, Wang T, Kurman R.J, Springer S, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Tanner E.J, Angarita A, Lycke M, Jochumsen K, Afsar B, Danilova L, Levine D.A, Jardon K, Zeng X, Arseneau J, Fu L, Diaz Jr L.A, Karchin R, Tomasetti C, Kinzler K.W, Vogelstein B, Fader A.N, Gilbert L, Papadopoulos N Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci. Transl. Med. 10, eaap8793 (2018)
VIEW ARTICLE

Date of Defence: 2020-04-24
Disputation: Fredagen den 24 april 2020, kl 9.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg
Degree: Doctor of Philosophy (Medicine)
Publication type: Doctoral thesis
Keywords: Ovarian neoplasms
EOC
Diagnosis
protein biomarkers
HE4
CA125
Algorithms
RMI
ROMA
NGS
rare mutations
liquid biopsies
screening
Abstract: Background: Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer. The 5-year survival is about 30%, a consequence of failure to establish early diagnosis due to unspecific symptoms. The biomarker serum CA125 and transvaginal ultrasound are used as the “golden standards” for assessing ovarian cysts and pelvic tumors of unknown origin, but early diagnosis is still not achieved and specificity is low. Increased knowledge about EOC specific mutations has revised our understanding of... more
ISBN: 978-91-7833-806-1 (Print)
978-91-7833-807-8 (PDF)
URI: http://hdl.handle.net/2077/63236
Appears in Collections:Doctoral Theses from Sahlgrenska Academy
Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper

 

 

© Göteborgs universitet 2011